Oct 23 2008, 4:00 AM EST
PRNEWSWIRE
--Honor recognizes excellence in ChIP, DNA methylation innovation and service--
The award recognizes Genpathway for providing superior services for chromatin immunoprecipitation (ChIP) and DNA methylation assays that directly contribute to discoveries in gene regulation, epigenetics, and gene transcription.
"Frost & Sullivan recognizes Genpathway for its outstanding efforts to provide researchers an efficient and economical solution to fast-track notoriously difficult ChIP procedures," explained Frost & Sullivan industry analyst
"Genpathway is honored to be recognized with this prestigious award from Frost & Sullivan," said
Frost & Sullivan presents its Annual Award for Innovation in Healthcare to the company that has introduced truly innovative products, practices, or ideas within its industry. The award recognizes the company's innovative contributions that make it possible to envision a new level of care in the diagnosis, treatment, and management of disease, leading to better outcomes and quality of life for patients; or that lead to improvements in the tools that clinicians, diagnosticians, researchers, and healthcare administrators have at their disposal to improve quality and efficiency in provision of healthcare services. The selection of this award is based on interviews and primary market analysis conducted by Frost & Sullivan's industry analyst team.
About Genpathway (www.genpathway.com)
Genpathway is a pharmacogenomics company that provides specialized drug discovery, research, and development services and develops novel diagnostic biomarkers that predict drug responses, enabling personalized treatments. The company applies its proprietary chromatin and methylated DNA immunoprecipitation (ChIP) technology to understand gene regulation and genetic pathways by studying transcription factor binding, gene transcription, and epigenetic events such as DNA methylation and histone modifications. Based on the information gained from its technology, Genpathway is developing and commercializing a broad portfolio of clinically validated molecular diagnostic products and services that will enable the accurate selection of specific drugs to efficaciously treat individuals with cancer, immune disorders, and other serious diseases.
About Frost & Sullivan (www.frost.com)
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting, and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.
Contact: Mary Moynihan M2Friend Biocommunications (802) 951-9600 mary@m2friend.com
SOURCE Genpathway
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All